The new 3C technology allows for “tailored omega-3 EPA and DHA high concentrates,” according to DSM.
Photo © iStockphoto.com/numbeos
DSM (Parsippany, NJ) has unveiled a new omega-3 process technology that it says allows for “tailored omega-3 EPA and DHA high concentrates.” The new 3C technology, which is suitable for both dietary supplements and pharmaceutical applications, allows for omega-3 concentrates of up to 85% and customizable ratios of EPA and DHA.
DSM adds that the “radically efficient” technology is designed to make high-concentrate omega-3 ingredients more accessible than ever by giving brand owners more versatility to tailor their products to meet consumer needs. The firms says its 3C technology “will be a catalyst for category growth by helping to eliminate key barriers to consumption of omega-3 supplements, such as capsule size.”
“This new technology truly makes the oversized pills of traditional fish oil with low EPA and DHA omega-3 content a thing of the past,” says Tobe Cohen, vice president of DSM Nutritional Products. DSM’s new technology debuted at the recent SupplySide West trade show.
Read more:
Omega-3 Ingredient Innovation at SupplySide West
2016 Omega-3 Market Update: Fish Oil, Krill Oil, Astaxanthin, and More
Widespread Omega-3 Usage Could Save €12.9 Billion in Annual EU Healthcare Costs, Study Suggests
The impact of GLP-1 on supplements, functional foods, and retail: a webinar from CRN
January 29th 2025The recent CRN webinar discussed GLP-1 medications' impact on supplements, functional foods, and retail, covering consumer trends, global market insights, retailer strategies, industry implications, and future opportunities for innovation.